Stryker Corporation : Stryker Receives FDA Warning Letter

          Stryker Corporation : Stryker Receives FDA Warning Letter

Kalamazoo, Michigan - March 12, 2013 - Stryker Corporation (NYSE: SYK)
announced today that its Instruments division has received a warning letter
from the U.S. Food and Drug Administration (FDA) related to observations made
during a November 2012 inspection at its Portage, Michigan location.

The letter concerns quality system observations made during the inspection and
cites Stryker for failing to notify the FDA of a product recall, and for
marketing devices, including the Neptune Waste Management System, without a
required 510(k) clearance. The letter acknowledged that Stryker Instruments
has already submitted corrective action plans for the quality system and
recall observations. The Company is fully cooperating with the FDA to resolve
these matters in a comprehensive and timely manner.

Stryker is one of the world's leading medical technology companies and is
dedicated to helping healthcare professionals perform their jobs more
efficiently while enhancing patient care. The Company offers a diverse array
of innovative medical technologies, including reconstructive, medical and
surgical, and neurotechnology and spine products to help people lead more
active and more satisfying lives. For more information about Stryker, please
visit www.stryker.com.

Contacts

For media inquiries please contact:
Yin Becker, Stryker Corporation, 201-831-5000 or yin.becker@stryker.com

For investor inquiries please contact:
Katherine A. Owen, Stryker Corporation, 269-385-2600 or
katherine.owen@stryker.com

Forward-Looking Statements

This press release contains information that includes or is based on
forward-looking statements within the meaning of the federal securities law
that are subject to various risks and uncertainties that could cause our
actual results to differ materially from those expressed or implied in such
statements. Such factors include, but are not limited to: weakening of
economic conditions that could adversely affect the level of demand for our
products; pricing pressures generally, including cost-containment measures
that could adversely affect the price of or demand for our products; changes
in foreign exchange markets; legislative and regulatory actions; unanticipated
issues arising in connection with clinical studies and otherwise that affect
U.S. Food and Drug Administration approval of new products; changes in
reimbursement levels from third-party payors; a significant increase in
product liability claims; the ultimate total cost with respect to the
Rejuvenate and ABG II matter; the impact of investigative and legal
proceedings and compliance risks; resolution of tax audits; the impact of the
federal legislation to reform the United States healthcare system and the 2.3
percent medical device excise tax; changes in financial markets; changes in
the competitive environment; our ability to integrate acquisitions, including
the acquisition of Trauson Holdings Company Limited; and our ability to
realize anticipated cost savings as a result of workforce reductions and other
restructuring activities. Additional information concerning these and other
factors are contained in our filings with the U.S. Securities and Exchange
Commission, including our Annual Report on Form 10-K and Quarterly Reports on
Form 10-Q.

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Stryker Corporation via Thomson Reuters ONE
HUG#1684698
 
Press spacebar to pause and continue. Press esc to stop.